Eyenovia Inc (EYEN)
0.4951
+0.03
(+6.93%)
USD |
NASDAQ |
Sep 27, 16:00
0.49
-0.01
(-1.03%)
After-Hours: 20:00
Eyenovia SG&A Expense (TTM): 13.74M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 13.74M |
March 31, 2024 | 13.13M |
December 31, 2023 | 12.43M |
September 30, 2023 | 12.20M |
June 30, 2023 | 12.61M |
March 31, 2023 | 12.99M |
December 31, 2022 | 13.53M |
September 30, 2022 | 14.02M |
June 30, 2022 | 13.04M |
March 31, 2022 | 11.80M |
December 31, 2021 | 10.57M |
September 30, 2021 | 8.871M |
June 30, 2021 | 8.226M |
March 31, 2021 | 8.033M |
Date | Value |
---|---|
December 31, 2020 | 7.626M |
September 30, 2020 | 7.634M |
June 30, 2020 | 7.395M |
March 31, 2020 | 7.100M |
December 31, 2019 | 7.206M |
September 30, 2019 | 7.300M |
June 30, 2019 | 7.643M |
March 31, 2019 | 6.742M |
December 31, 2018 | 6.137M |
September 30, 2018 | 4.659M |
June 30, 2018 | 3.141M |
March 31, 2018 | 2.457M |
December 31, 2017 | 1.316M |
September 30, 2017 | 0.9126M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
7.100M
Minimum
Mar 2020
14.02M
Maximum
Sep 2022
10.47M
Average
11.19M
Median
SG&A Expense (TTM) Benchmarks
NovaBay Pharmaceuticals Inc | 11.53M |
Reviva Pharmaceuticals Holdings Inc | 8.188M |
Palatin Technologies Inc | 13.34M |
iBio Inc | 11.67M |
Theriva Biologics Inc | 5.633M |